Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025: Annex 4: Questionnaire on NDP performance assessment

Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages)

Table of Contents

Executive summary
I. Introduction
II. Background on the research project
	1. Research questions and objectives of the study
	2. Study approach and research tools
	3. Project past activities
III. Second workshop
	1. Aim and objectives
	2. Participants
	3. Method of work and proceedings
IV. Preliminary findings
	1. The methods: What has been learnt?
		1.1 Methods in context: How did the country teams use the methods?
		1.2 Methods in question: What were the main problems encountered and how to solve them?
		1.3 Relevance of the methods
	2. National drug policies: what has been learnt?
		2.1 Preliminary findings based on NDP indicators
		2.2 Preliminary interpretations based on NDP indicators
		2.3 Preliminary findings based on the political mapping
	3. Cross national analysis: What can be learnt at this stage?
		3.1 Relevance of the methods for cross national comparison
		3.2 Strengths and weaknesses of NDP from a cross national perspective
		3.3 Tentative explanations for cross national variations
	4. Broader capacity building
V. Conclusions of the workshop and follow-up plans
	1. Main outcomes
	2. Next steps
Annex 1: Research proposal
	I. Introduction
	II. The Problem
	III. Research Question and Objectives of Proposed Study
	IV. Study Approach
	V. Anticipated Outcomes
	VI. Methods
	VII. Time Line and Resources
	Selected References
Annex 2: List of participants
Annex 3: Agenda
Annex 4: Questionnaire on NDP performance assessment
Annex 5: Achievements of the national drug policies in the 12 countries
	Bulgaria
	Chad
	Colombia
	Guinea
	India
	Mali
	Philippines
	Sri Lanka
	Thailand
	Viet Nam
	Zambia
	Zimbabwe
Annex 6: Consolidated tables
Other documents in the DAP Research Series

Annex 4: Questionnaire on NDP performance assessment

Second workshop on the research on the comparative analysis of NDP

1. The relevance of the method to assess your country's policy

1. Were you able through the use of the indicators to evaluate the outcomes of your NDP?

_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________

2. Were you able through the use of the indicators to assess the implementation of the NDP?

3. Did you find things you did not know about the NDP from the indicators?

4. Which aspects of the NDP were not covered by the indicators?

2. The findings:

Based on the data collected (ST, PR, OT indicators), there are at least four questions:

Please circle the correct number. 1 = does not work 5 = works very well
1. Has the policy achieved the objectives of:

	• Availability of essential drugs?	1	2	3	4	5

	• Accessibility to essential drugs?	1	2	3	4	5

	• Quality of drugs?	1	2	3	4	5

	• Rational use of drugs?	1	2	3	4	5

2. Which components of the policy work and which ones do not work (policy structures and processes)?

Please circle the correct number. 1 = does not work 5 = works very well
(a) Legislation and regulation	1	2	3	4	5

(b) Essential drugs selection and drug registration	1	2	3	4	5

(c) Drug allocation in the health budget/public sector financing policy	1	2	3	4	5

(d) Public sector procurement procedures	1	2	3	4	5

(e) Public sector distribution and logistics	1	2	3	4	5

(f) Pricing policy	1	2	3	4	5

(g) Information and continuing education on drug use	1	2	3	4	5
Comments, if needed: ___________________________________________________ ___________________________________________________ ___________________________________________________ ___________________________________________________ ___________________________________________________

3. What is your assessment of the strengths of the national drug policy?

_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________

4. What is your assessment of the weaknesses of the national drug policy?

_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________

3. The analysis and interpretations of the findings

	*Yes*	No

1. Are there components (a, b, c, d, e,...) which have received more attention and were implemented first? If yes, can you identify the reasons for this?
_________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________
2. Were there components (a, b, c, d, e,...) that were easy to implement and components that were difficult to implement? If yes, can you identify which ones and why?
_________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________
3. Are there components (a, b, c, d, e,...) which seem to have been more important for achieving the NDP objectives than others? If yes, can you explain why?
_________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________
4. Were there any linkages in performance across components, so that if one component was performing well, other also performed well? If yes, can you comment upon?
_________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________ _________________________________________________________________